IBRX FY 2014 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$9B

FY 2014 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$641,000+6.8% YoY

Gross Profit

$641,000100.0% margin

Operating Income

-$6M-969.1% margin

Net Income

-$6M-969.3% margin

EPS (Diluted)

$-0.02

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$61M

Total Liabilities

$2M

Stockholders' Equity

$58M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$641,000	$600,000	+6.8%
Gross Profit	$641,000	$347,000	+84.7%
Operating Income	-$6M	-$2M	-173.8%
Net Income	-$6M	-$2M	-203.5%